Tonix Pharmaceuticals saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an increase from 89 to 92.
How To Use Stock Charts To Stay Profitable And Protected
This unique rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against the rest of the market.
Decades of market research reveals that the best stocks typically have an 80 or higher RS Rating as they begin their biggest climbs.
While the stock is not near a proper buy zone right now, see if it goes on to form and break out of a proper chart pattern.
Tonix Pharmaceuticals showed 0% earnings growth in its most recent report, while sales growth came in at -2%.
Tonix Pharmaceuticals holds the No. 102 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and Eton Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
